AB209960

Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain

RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(9 Publications)

Anti-PD-L1 antibody [28-8] - Extracellular domain - Alexa Fluor® 647 conjugated (ab209960) is a rabbit recombinant monoclonal antibody detecting PD-L1 in Flow Cytometry, ICC/IF. Suitable for Human.

- Biophysical QC for unrivalled batch-batch consistency

View Alternative Names

CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1

2 Images

Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain (AB209960)

ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain (AB209960)

ab209960 staining PDL1 in CHO-PDL1 cells. The lower panels demonstrate that ab209960 does not cross react with un-transfected CHO cells.

The cells were fixed with 4% formaldehyde (10 min), permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated overnight at +4°C with ab209960 at 1/200 dilution (shown in red) and ab195887, Mouse monoclonal to alpha Tubulin (Alexa Fluor^® 488), at 1/250 dilution (shown in green). Nuclear DNA was labeled with DAPI (shown in blue).

Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).

Flow Cytometry - Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain (AB209960)

Flow Cyt

Lab

Flow Cytometry - Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain (AB209960)

Overlay histgram showing CHO (blue line) and CHO-PD-L1 transfected (red line) cells stained with ab209960.

The cells were incubated in 1x PBS / 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (ab209960, 1/100 dilution) for 30 min at 4°C.

Acquisition of >5,000 events were collected using a 17mW red Helium-Neon laser (633nm) and 660/20 bandpass filter.

Carrier free

Anti-PD-L1 antibody [28-8] - BSA and Azide free (Detector)
Carrier free

Anti-PD-L1 antibody [28-8] - BSA and Azide free
Carrier free

Anti-PD-L1 antibody [28-8] - Low endotoxin, Azide free
Unconjugated

Anti-PD-L1 antibody [28-8]
660 APC

APC Anti-PD-L1 antibody [28-8]
519 Alexa Fluor® 488

Alexa Fluor® 488 Anti-PD-L1 antibody [28-8]
565 Alexa Fluor® 555

Alexa Fluor® 555 Anti-PD-L1 antibody [28-8]
603 Alexa Fluor® 568

Alexa Fluor® 568 Anti-PD-L1 antibody [28-8]
617 Alexa Fluor® 594

Alexa Fluor® 594 Anti-PD-L1 antibody [28-8]
Biotin

Biotin Anti-PD-L1 antibody [28-8] (Detector)
519 FITC

FITC Anti-PD-L1 antibody [28-8]
HRP

HRP Anti-PD-L1 antibody [28-8]
578 PE

PE Anti-PD-L1 antibody [28-8]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

28-8

Isotype

IgG

Conjugation

Alexa Fluor® 647

Excitation/Emission

Ex: 650nm, Em: 665nm

Carrier free

Reacts with

Human, Human

Applications

Flow Cyt, ICC/IF

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100", "ICCIF-species-notes": "<p>This product gave a positive signal in CHO-PDL1 cells fixed with 4% formaldehyde (10 min)</p>", "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1/100", "FlowCyt-species-notes": "<p></p>" } } }

style

left-column

Product details

What is this antibody validated in?
Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain (ab209960) is a rabbit recombinant monoclonal antibody and is validated for use in Flow Cytometry (Flow Cyt), Immunocytochemistry/immunofluorescence (ICC/IF) in Human samples.

Related products
Antibody clone 28-8 is also available pre-conjugated to a variety of labels for your convenience – Anti-PD-L1 Alexa Fluor® 647 [28-8] - Extracellular domain (ab209960).

Other related products
We have a range of other formats of antibody clone [28-8] also available for your convenience: ab205921, APC - ab206967, Carrier free - ab209889, Alexa Fluor® 488 - ab209959, Alexa Fluor® 647 - ab209960, HRP - ab209961, PE - ab209962, Alexa Fluor® 555 - ab213358, Alexa Fluor® 568 - ab213359, Alexa Fluor® 594 - ab213360, FITC - ab224027, Carrier free - ab228413, Carrier free - ab278010, Alexa Fluor® 647 - ab303724, Carrier free - ab307495, Biotin - ab322788

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle|Store in the dark

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.

Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 10581077). Can also act as a transcription coactivator : in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed : 32929201).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28813410, PubMed : 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

See full target information CD274

style

left-column

Publications (9)

Recent publications for all applications. Explore the full list and refine your search

Journal of extracellular vesicles 14:e70129 PubMed40766981

2025

Extracellular Vesicle Protein Panel Enables Early Lung Cancer Detection in a Large Clinical Cohort.

Applications

Unspecified application

Species

Unspecified reactive species

Linxiao Han,Yuanlin Song,Lin Tong,Jiayuan Sun,Xiaoju Zhang,Shujing Chen,Ying Li,Ziqi Wang,Lei Gao,Qiaoliang Zhu,Yencheng Chao,Xiaocen Wang,Ge Zhang,Wensi Zhu,Ludan He,Jie Liu,Qin Wang,Zuoren Wu,Yuanyuan Ji,Chunxue Bai,Xiuzhen Lv,Jian Zhou

Scientific reports 12:21286 PubMed36494467

2022

Effects of small molecule-induced dimerization on the programmed death ligand 1 protein life cycle.

Applications

Unspecified application

Species

Unspecified reactive species

Ilean Chai,Dmytro Kornyeyev,Edward Hsieh,Gesham Magombedze,Lance Stapleton,Magdeleine Hung,Hyock Joo Kwon,Erin Stefanutti,JeanPhilippe Belzile,Gregg Czerwieniec,Adele Y Wang,Mariya Morar,Latesh Lad

Anticancer research 42:407-417 PubMed34969751

2022

High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter.

Applications

Unspecified application

Species

Unspecified reactive species

Mio Ikeda,Yasuhiro Koh,Jun Oyanagi,Shunsuke Teraoka,Masayuki Ishige,Yuu Fujimura,Kazuo Takeda,Nahomi Tokudome,Yuichi Ozawa,Hiroki Ueda,Nobuyuki Yamamoto

Cancer communications (London, England) 41:1354-1372 PubMed34347390

2021

MAGE-C3 promotes cancer metastasis by inducing epithelial-mesenchymal transition and immunosuppression in esophageal squamous cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Qingnan Wu,Weimin Zhang,Yan Wang,Qingjie Min,Hongyue Zhang,Dezuo Dong,Qimin Zhan

Science advances 6: PubMed33219024

2020

High-throughput single-EV liquid biopsy: Rapid, simultaneous, and multiplexed detection of nucleic acids, proteins, and their combinations.

Applications

Unspecified application

Species

Unspecified reactive species

Jian Zhou,Zuoren Wu,Jie Hu,Dawei Yang,Xiaoyan Chen,Qin Wang,Jie Liu,Maosen Dou,Wenjun Peng,Yuanyuan Wu,Wenhao Wang,Chenjian Xie,Ming Wang,Yuanlin Song,Hengshan Zeng,Chunxue Bai

Biochimica et biophysica acta. Molecular cell rese 1866:118526 PubMed31398408

2019

Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions.

Applications

ICC/IF

Species

Human

Shohreh Azadi,Hamidreza Aboulkheyr Es,Sajad Razavi Bazaz,Jean Paul Thiery,Mohsen Asadnia,Majid Ebrahimi Warkiani

Biosensors & bioelectronics 117:97-103 PubMed29890396

2018

A flow-proteometric platform for analyzing protein concentration (FAP): Proof of concept for quantification of PD-L1 protein in cells and tissues.

Applications

Unspecified application

Species

Unspecified reactive species

Chao-Kai Chou,Po-Jung Huang,Pei-Hsiang Tsou,Yongkun Wei,Heng-Huan Lee,Ying-Nai Wang,Yen-Liang Liu,Colin Shi,Hsin-Chih Yeh,Jun Kameoka,Mien-Chie Hung

International journal of cancer 143:1741-1752 PubMed29667169

2018

Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.

Applications

IHC-P

Species

Human

Linnéa La Fleur,Vanessa F Boura,Andrey Alexeyenko,Anders Berglund,Victor Pontén,Johanna S M Mattsson,Dijana Djureinovic,Johan Persson,Hans Brunnström,Johan Isaksson,Eva Brandén,Hirsh Koyi,Patrick Micke,Mikael C I Karlsson,Johan Botling

BMC cancer 17:333 PubMed28511705

2017

PD-L1 expressing circulating tumour cells in head and neck cancers.

Applications

ICC/IF

Species

Human

Arutha Kulasinghe,Chris Perry,Liz Kenny,Majid E Warkiani,Colleen Nelson,Chamindie Punyadeera

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain

Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain (AB209960)

Flow Cytometry - Alexa Fluor® 647 Anti-PD-L1 antibody [28-8] - Extracellular domain (AB209960)

Related conjugates and formulations (13)

Key facts

Host species

Clonality

Clone number

Isotype

Conjugation

Excitation/Emission

Carrier free

Reacts with

Applications

Immunogen

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Assay Kits

Primary Antibodies

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (9)

Product promise